ReviewInternational journal of molecular sciences2020
Pyrazoline Hybrids as Promising Anticancer Agents: An Up-to-Date Overview.
Review in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed.
- Three privileged scaffolds, one pipeline: chalcones, pyrazolines and pyrazoles in drug discovery and fluorescent sensing.RSC medicinal chemistry · 2026Review
- Design, synthesis, anticancer activity and molecular modeling of new pyrazoline derivatives as telomerase inhibitors.RSC advances · 2026Article
- Study on Synthesis, Antiproliferative Properties, Immunomodulatory Effects, and Anti-Breast Cancer Activity of New ΔChemistry & biodiversity · 2026Article
- Discovery of a Novel 4,5-Dihydro-1Biomedicines · 2026Article
- 2-Pyrazoline-5-One Derivative Suppresses Cell Proliferation and Induces Apoptosis With Upregulation of Bax in Breast Cancer Cells.Journal of biochemical and molecular toxicology · 2026Article
- Heteroaromatic Pyrazole-Based Carbohydrazones: Structure-Dependent Redox Activity, DNA-Associated Spectroscopic Behavior, and Multifunctional Biological Properties.Molecules (Basel, Switzerland) · 2026Article
- Investigation of Novel Antiproliferative Drugs Interaction with mPEGJournal of chemical information and modeling · 2026Article
- The Pyrazole Scaffold in Anticancer Drug Discovery: A Review of Synthetic Approaches, Structure-Activity Relationships, and Target-Based Mechanism of Action.International journal of molecular sciences · 2026Review
- Multifaceted Anticancer Activity of Flavanone/Chromanone Intermediates for Five-Membered Heterocyclic Derivatives: Targeting Oxidative Stress, Apoptosis, and MAPK Signaling in Colorectal Cancer.Molecules (Basel, Switzerland) · 2026Article
- A Review of Research from 2012 to 2024 on Pyrazole-based Anticancer Agents with SAR Study.Current topics in medicinal chemistry · 2026Review
- NovelCancer drug resistance (Alhambra, Calif.) · 2026Article
- Pyrazole and Pyrazoline-Based EGFR TK Inhibitors: A Review Study Emphasizing Structure-Activity Relationship (SAR).Medicinal chemistry (Shariqah (United Arab Emirates)) · 2026Review
- Structure-activity Relationship of Substituted Pyrazoline Derivatives as Small Molecule Tyrosine Kinase Inhibitors.Current medicinal chemistry · 2026Review
- Secosteroid-2-Pyrazoline Hybrids: Design, Synthesis, Biological Evaluation and Development of Therapeutic Combinations Against ERα-Positive Breast Cancer Cells.Biomedicines · 2025Article
- Recent advances in non-conventional synthesis of N-heterocyclic compounds: emerging strategies and biological perspectives.RSC advances · 2025Review
- Exploring pyrazolines as potential inhibitors of NSP3-macrodomain of SARS-CoV-2: synthesis and in silico analysis.Scientific reports · 2025Article
- Article
- The activity of pyrazoline B compound in inhibiting proliferation of breast cancer cells with human epidermal growth factor receptor 2 overexpression.Contemporary oncology (Poznan, Poland) · 2025Article
- Pyrazoline B Induces Oxidative Stress Mediated Toxicity, Cell Cycle Arrest, and Caspase-Independent Apoptosis in BT-474 Human Breast Cancer Cells.Journal of experimental pharmacology · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pyrazolines are five-membered heterocycles possessing two adjacent nitrogens. They have attracted significant attention from organic and medicinal chemists due to their potent biological activities and the numerous possibilities for structural diversification. In the last decade, they have been intensively studied as targets for potential anticancer therapeutics, producing a steady yearly rise in the number of published research articles. Many pyrazoline derivatives have shown remarkable cytotoxic activities in the form of heterocyclic or non-heterocyclic based hybrids, such as with coumarins, triazoles, and steroids. The enormous amount of related literature in the last 5 years prompted us to collect all these published data from screening against cancer cell lines, or protein targets like EGFR and structure activity relationship studies. Therefore, in the present review, a comprehensive account of the compounds containing the pyrazoline nucleus will be provided. The chemical groups and the structural modifications responsible for the activity will be highlighted. Moreover, emphasis will be given on recent examples from the literature and on the work of research groups that have played a key role in the development of this field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.